RecruitingPhase 1NCT07728487
Study of AT-587 in Healthy Subjects
A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants
Sponsor
Atea Pharmaceuticals, Inc.
Enrollment
62 participants
Start Date
Jul 13, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria4
- Body mass index (BMI) of 18-29 kg/m2
- Must agree to use protocol-specified methods of contraception
- Negative pregnancy test
- Willing to comply with the study requirements and to provide written informed consent
Exclusion Criteria4
- Pregnant or breastfeeding
- Abuse of alcohol or drugs
- Use of other investigational drugs within 30 days of dosing
- Other clinically significant medical conditions
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAT-587
Parallel Assignment
OTHERPlacebo
Parallel Assignment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07728487
Related Trials
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT073589101 location
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
NCT064574381 location
Exposure to Hepatitis E Virus in Occitania, France
NCT061373131 location